본문으로 건너뛰기
← 뒤로

Low-Dose Bevacizumab in HCC: Unresolved Questions on Hepatic Reserve, Cost Claims, and LRT Heterogeneity.

Liver international : official journal of the International Association for the Study of the Liver 2026 Vol.46(5) p. e70651 Hepatocellular Carcinoma Treatment a
OpenAlex 토픽 · Hepatocellular Carcinoma Treatment and Prognosis Colorectal Cancer Treatments and Studies Hepatitis B Virus Studies

Zhao J, Liu L

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Jiajing Zhao, Liping Liu (2026). Low-Dose Bevacizumab in HCC: Unresolved Questions on Hepatic Reserve, Cost Claims, and LRT Heterogeneity.. Liver international : official journal of the International Association for the Study of the Liver, 46(5), e70651. https://doi.org/10.1111/liv.70651
MLA Jiajing Zhao, et al.. "Low-Dose Bevacizumab in HCC: Unresolved Questions on Hepatic Reserve, Cost Claims, and LRT Heterogeneity.." Liver international : official journal of the International Association for the Study of the Liver, vol. 46, no. 5, 2026, pp. e70651.
PMID 42003603
DOI 10.1111/liv.70651

같은 제1저자의 인용 많은 논문 (5)